DISCOVER

Vascepa

EXPERIENCED

in lipid science

INVESTOR

relations

Vascepa

LIPID SCIENCE

investor relations

welcome


therapeutics to improve cardiovascular health

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl) is Amarin's first FDA approved product and is available in the United States by prescription. For more information about Vascepa visit www.vascepa.com.

recent news


12 Jun 2018

Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications MORE

7 Jun 2018

Amarin Sponsors Three Scientific Presentations Scheduled for American Diabetes Association Scientific Sessions MORE

Stock Information

Symbol:
AMRN (NASDAQ)
Quote:
3.40
Change:
-0.08
Date:
4:00 PM EDT, Jun 12, 2018
(20 minute delayed share price)
Investor
Relations
Executive
Team
Career
Opportunities
Contact
Amarin

Amarin
Corporation

therapeutics to improve
cardiovascular health.

Join Our Mailing List

You may automatically receive Amarin Corporation plc financial information by email.


Click To Subscribe